

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE S.
04 FEB 25 PM 3:13:00
00000480802

LOBBYING REGISTRATION

Lobbying Disclosure Act of 1995 (Section 4)

Check if this is an Amended Registration

1. Effective Date of Registration 1/5/2004

2. House Identification Number _____

Senate Identification Number _____

REGISTRANT

3. Registrant name Novo Nordisk Pharmaceuticals, Inc.

Address 2401 Pennsylvania Avenue NW, Suite 300

City Washington

State DC

Zip 20037

4. Principal place of business (if different from line 3)

City Princeton

State/Zip (or Country) _____

5. Telephone number and contact name

(202) 663-7851

Contact Michael Mawby

E-mail (optional) mmby@

6. General description of registrant's business or activities

Pharmaceutical Sales

CLIENT *A Lobbying firm is required to file a separate registration for each client. Organizations employing in-house lobbyists should labeled "Self" and proceed to line 10.* **Self**

7. Client name

Address _____

City _____

State _____

Zip _____

8. Principal place of business (if different from line 7)

City _____

State/Zip (or Country) _____

9. General description of client's business or activities

LOBBYISTS

10. Name of each individual who has acted or is expected to act as a lobbyist for the client identified on line 7. If any this section has served as a "covered executive branch official" or "covered legislative branch official" within tv acting as a lobbyist for the client, *state the executive and/or legislative position(s) in which the person served.*

Name	Covered Official Position (if appli
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs

Form LD-1 (Rev 06/98)

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name _____

LOBBYING ISSUES

11. General lobbying issue areas. Select all applicable codes listed in instructions and on the reverse side of Form LL

HCR MMM BUD CPT

12. Specific lobbying issues (current and anticipated)

BUD - FY 2005 Appropriations for HHS diabetes related activities.
 CPT - H.R. 1561, the United States Patent and Trademark Fee Modernization Act of 2003; related patent, trademark and intellectual property issues.
 HCR - S.1666, Diabetes Prevention and Treatment Act of 2003; all sections. HR 1916, Diabetes Prevention Access and Care Act; all sections. HR 3194, Diabetes Self-Management 2003; all sections.
 MMM - Regulations related to implementing each of the diabetes provisions of the Medicare Prescription Drug and Modernization Act of 2003 with a special emphasis on ensuring that pertaining to the definition of insulin delivery devices as a covered drug reflect the sense of Congress as embodied in the conference report.

AFFILIATED ORGANIZATIONS

13. Is there an entity other than the client that contributes more than \$10,000 to the lobbying activities of the registrant in a semiannual period and in whole or in major part plans, supervises or controls the registrant's lobbying

No ⇒ Go to line 14. Yes ↓ Complete the rest of this section for each entity meeting the criteria above, then proceed to line 14.

Name	Address	Principal Place of Business (city and state or country)

FOREIGN ENTITIES

14. Is there any foreign entity that:

- a) holds at least 20% equitable ownership in the client or any organization identified on line 13;
- b) directly or indirectly, in whole or in major part, plans, supervises, controls, directs, finances or otherwise influences the lobbying activities of the client or any organization identified on line 13; **OR**
- c) is an affiliate of the client or any organization identified on line 13 and has a direct interest in the lobbying activity?

No ⇒ Sign and date the registration. Yes ↓ Complete the rest of this section for each foreign entity matching the criteria above, then sign and date registration.

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities
Novo Nordisk A/S	Novo Alle	2880 Bagsvaerd Denmark	\$0.00

Signature Michael Mawby Date 02/20/21

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

Form LD-1 (Rev. 06/98)